We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 130.72 | 2,776 | 12:36:18 |
From Apr 2019 to Apr 2024
By Adriano Marchese
Merck & Co. said Monday that it is voluntarily withdrawing the U.S. indication for KEYTRUDA for the treatment of patients with metastatic small cell lung cancer after failing to meet an endpoint in its phase three trials.
The company said the withdrawal of the indication of KEYTRUDA--a therapy also known as pembrolizumab--was done in consultation with the Food and Drug Administration, and Merck expects to complete the process over the coming weeks.
The company noted that phase three trials met only one of its dual primary endpoints, failing reach statistical significance for the other endpoint.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 01, 2021 16:50 ET (21:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
